1.23

2.50% 0.03

Phio Pharmaceuticals Corp (PHIO)

Overview News Price History Financials Why PHIO Down? Discussions Forecast Stock Split

Phio Pharmaceuticals Corp stock is traded at $1.23, with a volume of 374.22K. It is up +2.50% in the last 24 hours and down -41.98% over the past month. Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

Previous Close:

$1.20

Open:

$1.21

24h Volume:

374.22K

Relative Volume:

0.14

Market Cap:

$13.24M

Revenue:

Net Income/Loss:

$-11.66M

P/E Ratio:

-0.1508

EPS:

-8.156

Net Cash Flow:

$-11.09M

1W Performance:

-1.60%

1M Performance:

-41.98%

6M Performance:

-29.71%

1Y Performance:

-51.00%

1-Day Range:

$1.20

$1.29

1-Week Range:

$1.08

$1.29

52-Week Range:

$0.9657

$9.79

Phio Pharmaceuticals Corp Stock (PHIO) Company Profile

Name

Phio Pharmaceuticals Corp

Sector

Healthcare (1136)

Industry

Biotechnology (634)

Phone

(508) 767-3861

Address

411 SWEDELAND ROAD, KING OF PRUSSIA, MA

Employee

Twitter

@phio_pharma

Next Earnings Date

2024-11-07

Latest SEC Filings

PHIO's Discussions on Twitter

Compare PHIO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PHIO Phio Pharmaceuticals Corp	1.23	12.92M	0	-11.66M	-11.09M	-8.156
VRTX Vertex Pharmaceuticals Inc	432.17	109.05B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	784.61	82.75B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	445.12	56.78B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	917.63	56.52B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	204.51	44.58B	447.02M	-1.18B	-906.14M	-6.1812

Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-05-25	Resumed	H.C. Wainwright	Buy
Aug-05-20	Initiated	H.C. Wainwright	Buy

Phio Pharmaceuticals Corp Stock (PHIO) Latest News

06:38 AM

How Phio Pharmaceuticals Corp. stock responds to policy changesMarket Risk Report & Fast Gain Swing Alerts - BỘ NỘI VỤ

06:38 AM

Nov 25, 2025

Phio Pharmaceuticals Completes Enrollment for PH-762 Trial - TipRanks

Nov 25, 2025

Phio Pharmaceuticals Completes Enrollment in Phase 1b Trial of PH-762 - TradingView

Nov 25, 2025

Phio completes enrollment in Phase 1b trial of skin cancer therapy - Investing.com Australia

Nov 25, 2025

Phio completes enrollment in Phase 1b trial of skin cancer therapy By Investing.com - Investing.com South Africa

Nov 25, 2025

Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 - Newsfile

Nov 25, 2025

Phio Pharmaceuticals (NASDAQ: PHIO) Reports PH-762 Data With 6 Complete Responses - Stock Titan

Nov 25, 2025

Nov 24, 2025

[Form 4] Phio Pharmaceuticals Corp. Insider Trading Activity - Stock Titan

Nov 24, 2025

It is Poised to be a Bull Market for Phio Pharmaceuticals Corp (PHIO) - Setenews

Nov 24, 2025

What is HC Wainwright’s Forecast for PHIO FY2025 Earnings? - Defense World

Nov 24, 2025

Nov 21, 2025